Sakata Hideaki, Hayashi Ken, Matsuyama Ryo, Omata Tomoyo, Kanou Masanobu, Yamana Kei, Kanzaki Sho
Kawagoe Ear Institute, Division of Otorhinolaryngology, Kawagoe Mine Medical Center, Kawagoe City, Saitama 350-1122, Japan.
Nutraceutical Group, New Business Development Unit, Teijin Limited, Hino, Tokyo, Japan.
J Clin Med Res. 2024 Dec;16(11):519-526. doi: 10.14740/jocmr6083. Epub 2024 Nov 11.
Hearing loss prevalence increases with age, affecting over 25% of the global population aged 60 years or older. The aim of the study was to investigate the association between the development of sensorineural hearing loss (SNHL) and the blood levels of nicotinamide adenine dinucleotide (NAD).
A single-center, observational study was conducted at Kawagoe Otology Institute in Japan. A total of 80 patients were included and allocated to four groups of 20 patients each: patients aged 50 - 79 years with or without unilateral sudden sensorineural hearing loss (SSNHL), and patients aged ≥ 80 years with or without bilateral age-related hearing loss (ARHL). The distribution of whole-blood NAD levels was investigated. We also measured oxidative stress markers (diacron-reactive oxygen metabolites (dROMs) and biological antioxidant potential (BAP)) and examined the relationship between the development of SNHL and whole-blood NAD levels, dROMs, and BAP.
Comparison of NAD levels with and without hearing loss in the same age group by analysis of covariance showed a significantly lower NAD level in those with hearing loss than those without in the ≥ 80 age group (P = 0.047), whereas there was no difference between the two groups in the 50 - 79 age group (P = 0.232). All 80 patients, without consideration of age or type of hearing loss, were subjected to multivariate analysis to explore factors contributing to the development of hearing loss. With each 1 µM increase in the NAD level, the probability of developing SNHL decreased to 0.9-fold (P = 0.047), and each 1 U.CARR increase in dROMs was associated with a 1.01-fold increase in the risk of developing SNHL (P = 0.014). Whole-blood NAD levels in ARHL patients were significantly lower than those in non-ARHL patients. There was no association between whole-blood NAD and dROMs or BAP levels. This study has some limitations, including a sample size that was not large enough to detect a significant difference and an imbalance in the male-to-female ratio.
Decreased amount of NAD in the body and increased dROMs levels were associated with increased risk of developing SNHL, and the development of ARHL was especially highly associated with a decreased amount of NAD in the body.
听力损失患病率随年龄增长而增加,影响全球超过25%的60岁及以上人口。本研究的目的是调查感音神经性听力损失(SNHL)的发生与烟酰胺腺嘌呤二核苷酸(NAD)血液水平之间的关联。
在日本川越耳科学研究所进行了一项单中心观察性研究。共纳入80例患者,分为四组,每组20例:50 - 79岁有或无单侧突发性感音神经性听力损失(SSNHL)的患者,以及≥80岁有或无双侧年龄相关性听力损失(ARHL)的患者。研究了全血NAD水平的分布情况。我们还测量了氧化应激标志物(二丙烯反应性氧代谢产物(dROMs)和生物抗氧化潜力(BAP)),并研究了SNHL的发生与全血NAD水平、dROMs和BAP之间的关系。
通过协方差分析比较同一年龄组有听力损失和无听力损失者的NAD水平,结果显示≥80岁年龄组中,有听力损失者的NAD水平显著低于无听力损失者(P = 0.047),而50 - 79岁年龄组两组之间无差异(P = 0.232)。对所有80例患者,不考虑年龄或听力损失类型,进行多因素分析以探讨导致听力损失发生的因素。NAD水平每增加1 μM,发生SNHL的概率降低至0.9倍(P = 0.047),dROMs每增加1 U.CARR,发生SNHL的风险增加1.01倍(P = 0.014)。ARHL患者的全血NAD水平显著低于非ARHL患者。全血NAD与dROMs或BAP水平之间无关联。本研究存在一些局限性,包括样本量不够大以至于无法检测到显著差异以及男女比例不均衡。
体内NAD量减少和dROMs水平升高与发生SNHL的风险增加相关,且ARHL的发生尤其与体内NAD量减少高度相关。